Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma

被引:33
作者
Kindler, HL [1 ]
机构
[1] Univ Chicago, Med Ctr, Dept Hematol Oncol, Chicago, IL 60637 USA
关键词
novel cytostatic agents; vascular endothetial; growth factor; epidermal growth factor; platelet derived growth factor; tyrosine kinase;
D O I
10.1016/j.lungcan.2004.04.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is now known that vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in malignant mesothelioma; epidermal growth factor receptor (EGFR) is also highly overexpressed. Cytotoxic drugs that target these growth factors offer fresh potential for the treatment of mesothelioma. Clinical trials have recently been initiated to evaluate the anti-tumour activity of the VEGF inhibitors SU5416, bevacizumab and thalidomide. ZD1839 (Iressa, AstraZeneca), an inhibitor of EGFR tyrosine kinase, is also being evaluated. Two clinical trials are planned to evaluate the two PDGF inhibitors Gleevec (Imatinib mesylate, STI-571, Novartis Pharmaceuticals) and PTK787 (Novartis Pharmaceuticals). (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S125 / S127
页数:3
相关论文
共 19 条
  • [11] Linder C, 1998, ANTICANCER RES, V18, P2063
  • [12] Mutsaers SE, 1997, EUR J CELL BIOL, V72, P24
  • [13] VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
    Ohta, Y
    Shridhar, V
    Bright, RK
    Kalemkerian, GP
    Du, W
    Carbone, M
    Watanabe, Y
    Pass, HI
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (01) : 54 - 61
  • [14] Chemotherapy in malignant pleural mesothelioma: A review
    Ong, ST
    Vogelzang, NJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 1007 - 1017
  • [15] Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
    Strizzi, L
    Catalano, A
    Vianale, G
    Orecchia, S
    Casalini, A
    Tassi, G
    Puntoni, R
    Mutti, L
    Procopio, A
    [J]. JOURNAL OF PATHOLOGY, 2001, 193 (04) : 468 - 475
  • [16] VERMEULEN PB, 1996, P AN M AM SOC CLIN, V15, P90
  • [17] VERSNEL MA, 1991, ONCOGENE, V6, P2005
  • [18] Wood JM, 2000, CANCER RES, V60, P2178
  • [19] [No title captured]